## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.8% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($72.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Henry Schein, Inc. (HSIC): A Bull Case Theory**
- Source: Insider Monkey | 20251209T143700 | Bullish | Relevance: 99%
- This article summarizes a bullish thesis on Henry Schein, Inc. (HSIC), highlighting the company's undervalued stock price, near-term catalysts like a new CEO, and growth opportunities such as private-label expansion and AI-driven software. Despite stagnant end-market growth, the company is poised for EPS growth exceeding $7 within two to three years through strategic improvements and a share repurchase program. Investors are encouraged to consider HSIC's robust market position and defensive industry exposure for potential upside.

**2. Why Henry Schein (HSIC) Stock Is Up Today**
- Source: The Globe and Mail | 20251210T060833 | Somewhat-Bullish | Relevance: 98%
-  Shares of Henry Schein (NASDAQ:HSIC), a dental and medical products company, rose 2.8% after Barclays initiated coverage with an 'Overweight' rating and an $86 price target. The company also announced an extension of its strategic partnership with KKR. This positive news follows a previous stock gain related to hopes for an interest rate cut from the Federal Reserve.

**3. Why Henry Schein (HSIC) Stock Is Up Today**
- Source: TradingView | 20251209T210751 | Bullish | Relevance: 98%
-  Shares of Henry Schein (HSIC) rose by 2.8% after Barclays initiated coverage with an 'Overweight' rating and an $86 price target, signaling a positive outlook for the company's growth. The company also extended its strategic partnership with KKR, with KKR's designees to be renominated to the board. Despite recent gains, HSIC is still trading below its 52-week high.

**4. Henry Schein to renominate KKR designees to board for 2026 term By Investing.com**
- Source: Investing.com South Africa | 20251209T130809 | Bullish | Relevance: 98%
- Henry Schein Inc. announced it will renominate Max Lin and William K. Daniel, KKR designees, for election to its board of directors at the company's 2026 annual meeting, with their term expiring at the 2027 meeting. This decision follows an extension exercised by KKR Hawaii Aggregator L.P. under a Strategic Partnership Agreement. The company also recently reported strong Q3 2025 earnings and expanded its distribution agreement with vVARDIS.

**5. Henry Schein, Inc. (HSIC): A Bull Case Theory**
- Source: Finviz | 20251209T200814 | Bullish | Relevance: 97%
-  This article summarizes a bullish thesis for Henry Schein, Inc. (HSIC), highlighting its current undervaluation at 13x EPS despite being the largest dental distributor in the U.S. Key growth catalysts include the upcoming announcement of a new CEO, increased private-label penetration, cost optimization, and AI-driven growth through its dental software business. The company also benefits from an ongoing share repurchase program, suggesting a path to over $7 EPS within two to three years and offering a favorable risk/reward profile for investors.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.9% to 2.8% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >3.0% for momentum thesis). MRS_5 at 2.2% confirms short-term momentum alignment. Outperforming sector by 5.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.80% (CS: 69) | Neutral |
| RSI_14 | 65.9 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.24
- **Stop Loss:** $72.86 (4.4% risk)
- **Target:** $79.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 408
- **Position Value:** $31,105.92
- **Portfolio %:** 31.11%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*